Cite
HARVARD Citation
Suarez, C. et al. (n.d.). 873PSafety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. Annals of oncology. p. . [Online].